Komori
Zeria Pharmaceutical (4559) · PolicyRestated

Application of the Revenue Recognition Accounting Standards, etc.

First written in FY2022-Q1. 3 of 4 entries say "Restated". Latest entry: FY2023.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20232021: 220212022: 120222023: 12023
Same theme, other companies

The whole theme swung hardest in 2025: 2 of 9 companies on the "Worse" side.

49 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 83 companies compared. The sentences above are computed from all 83.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「Revenue is measured at the amount of consideration promised in contracts with customers, less returns, discounts, rebates and other items.」

    The Company continues to disclose its revenue recognition method, under which returns, discounts and rebates are deducted following application of the revenue recognition standard.
  2. FY2022-Q3RestatedAnnual report

    「The Accounting Standard for Revenue Recognition (Accounting Standard No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Standard”) and other standards were applied from the beginning of the first quarter of the consolidated fiscal year. Revenue is now recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The Company continues to disclose the application of the revenue recognition standard and the change to deduct sales incentives and other items from revenue and not recognise revenue when products are returned.
  3. FY2022-Q2RestatedAnnual report

    「The Accounting Standard for Revenue Recognition (Accounting Standard No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Standard”) and other standards were applied from the beginning of the first quarter of the consolidated fiscal year. Revenue is now recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The Company continues to disclose the application of the revenue recognition standard and the change to deduct sales incentives and other items from revenue and not recognise revenue when products are returned.
  4. FY2022-Q1First statedAnnual report

    「We adopted the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and related standards from the beginning of the first quarter of the current fiscal year and began recognizing revenue at the amount expected to be received in exchange for the promised goods or services when control of those goods or services transfers to the customer.」

    From 1 April 2021, the Company applied the accounting standard for revenue recognition and related standards, changing the recognition and presentation of revenue by deducting sales incentives and other items from revenue and not recognising revenue for returns.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.